Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma is a promising company with a strong commercialization strategy for their CAR-T candidate, ronde-cel, and their development of LYL273 for mCRC. Their focus on competing with current CAR-T therapies and seeking accelerated approval, along with the potential efficacy and safety of their treatments, make them a favorable investment opportunity. The company's acquisition of control over their manufacturing process and investment in R&D also show dedication to their success in the competitive cell therapy market.

Bears say

Lyell Immunopharma is a cell therapy company with potential in the treatment of cancer. While the development of ronde-cel and the success of other therapies are promising, the company faces potential risks in obtaining regulatory approvals and securing funding. There is also a risk of insolvency and decreased share price if the company is unable to raise enough capital, despite strong leadership from the lead independent director. Additionally, risks related to intellectual property and clinical trials should be considered when evaluating the potential of this stock.

Lyell Immunopharma (LYEL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.